Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

v3.23.3
Accrued Expenses
9 Months Ended
Sep. 30, 2023
Payables and Accruals [Abstract]  
Accrued Expenses

9. Accrued Expenses

Accrued expenses consisted of the following as of September 30, 2023 and December 31, 2022 (in thousands):

 

 

September 30, 2023

 

 

December 31, 2022

 

External research and preclinical development

 

$

11,643

 

 

$

8,219

 

Employee compensation and benefits (Note 13)

 

 

7,941

 

 

 

8,529

 

Professional fees

 

 

1,300

 

 

 

1,164

 

Facilities and other

 

 

605

 

 

 

54

 

Accrued expenses

 

$

21,489

 

 

$

17,966